NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017
July 07 2017 - 7:00AM
NewLink Genetics Corporation (NASDAQ:NLNK), today announced
that it will release its second quarter 2017 financial results
on Friday, July 28, 2017. The company has scheduled a
conference call for 8:30 AM ET the same day to discuss
the results and to give an update on its clinical and development
activities.
NewLink Genetics' senior management team will host the
conference call, which will be open to all listeners. There will
also be a question and answer session following the prepared
remarks.
Access to the live conference call is available by dialing (855)
469-0612 (U.S.) or (484) 756-4268 (international) five minutes
prior to the start of the call. The conference call will be webcast
live and a link can be accessed through the NewLink
Genetics website
at http://edge.media-server.com/m/p/mqa6eh65. A replay
of the call will be available for two weeks from the date of the
call and can be accessed by dialing (855) 859-2056 (U.S.) or (404)
537-3406 (international) and using the passcode 51432155.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company
focusing on discovering, developing and commercializing novel
immuno-oncology product candidates to improve the lives of patients
with cancer. NewLink Genetics' IDO pathway inhibitors are
designed to harness multiple components of the immune system to
combat cancer. Indoximod is being evaluated in combination
with treatment regimens including anti-PD-1 agents, cancer
vaccines, and chemotherapy across multiple indications such as
melanoma, prostate cancer, acute myeloid leukemia, and pancreatic
cancer. For more information, please
visit http://www.newlinkgenetics.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements
of NewLink Genetics that involve substantial risks and
uncertainties. All statements, other than statements of historical
facts, contained in this press release are forward-looking
statements, within the meaning of The Private Securities Litigation
Reform Act of 1995. The words "anticipate," "believe," "estimate,"
"expect," "intend," "may," "plan," "target," "potential," "will,"
"could," "should," "seek" or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include
any statements other than statements of historical fact. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that NewLink Genetics makes due to a number of
important factors, including those risks discussed in "Risk
Factors" and elsewhere in NewLink Genetics' Annual Report
on Form 10-K for the year ended December 31, 2016 and
other reports filed with the U.S. Securities and Exchange
Commission (SEC). The forward-looking statements in this press
release represent NewLink' Genetics' views as of the date
of this press release. NewLink Genetics anticipates that
subsequent events and developments will cause its views to change.
However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing NewLink
Genetics' views as of any date subsequent to the date of this
press release.
Investor Contacts:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com
Beth Kurth
LaVoieHealthScience
617-374-8800, ext. 106
bkurth@lavoiehealthscience.com
Media Contact:
Andrew Mastrangelo
LaVoieHealthScience
617-374-8800, ext. 108
amastrangelo@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024